Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or "the Company"), a fully integrated, commercial-stage biotechnology company, today announced a major managed Medicare agreement for TONMYA® (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.). The new agreement will go into effect on January 1, 2027. On top of two prior commercial coverage agreements with leading group purchasing organizations (GPOs) effective in the second quarter of 2026, and Medicaid availability in most states representing approximately 73 million lives, pharmacy coverage for TONMYA on January 1, 2027, will total approximately 145 million covered lives (46% of 314 million covered lives). Discussions with other commercial and Medicare payers continue to advance.

Following these coverage milestones and positive trends across the launch’s key performance indicators, Tonix is executing its strategy to incrementally grow the TONMYA sales force and expects to deploy 50 new sales force representatives in the field by mid-third quarter 2026, bringing the full sales force to approximately 150 people.